Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BosuPeg trial of bosutinib with or without ropeginterferon alfa-2b in newly diagnosed chronic myeloid leukemia
2024-517417-32-00Phase 2Authorised
- Sponsor
- St. Olavs University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Bosutinib alone with Bosutinib plus ropeginterferon alfa-2b (2 arms). Primary endpoint: MR4 rate at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
ropeginterferon alfa-2bbosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-517417-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517417-32-00.